Get started
Taysha Gene Therapies, Inc.TT

Taysha Gene Therapies, Inc.

1.88USDR
+0.08+4.44%
At close at Mar 27, 23:46 GMT
USD
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals Options

TSHA fundamentals

Key facts

Market capitalization‪385.40 M‬USD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.38USD
Founded2019
Employees (FY)73
CEOSean P. Nolan
Websitetayshagtx.com
About

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Ownership
‪‪205.00 M‬‬
Free Float shares
‪‪165.01 M‬‬ (80.49%)
Closely held shares
‪‪39.99 M‬‬ (19.51%)
Free Float shares
‪‪165.01 M‬‬ (80.49%)
Closely held shares
‪‪39.99 M‬‬ (19.51%)
Capital structure
Market cap
‪‪385.40 M‬‬
Debt
‪‪63.95 M‬‬
Cash & equivalents
‪‪139.49 M‬‬
Enterprise value
‪‪309.87 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪385.40 M‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
44.27x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
44.27x
Valuation ratios
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪15.00‬
‪30.00‬
‪45.00‬
‪60.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−2,000%‬
‪−1,000%‬
‪0%‬
‪1,000%‬
‪2,000%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−50.00 M‬‬
‪‪−25.00 M‬‬
‪0.00‬
‪‪25.00 M‬‬
‪‪50.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−21.00 M‬‬
‪‪−14.00 M‬‬
‪‪−7.00 M‬‬
‪0.00‬
‪‪7.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−21.00 M‬‬
‪‪−14.00 M‬‬
‪‪−7.00 M‬‬
‪0.00‬
‪‪7.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Gene Therapy
By country
Period: 2024
United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪900.00 K‬‬
‪‪1.80 M‬‬
‪‪2.70 M‬‬
‪‪3.60 M‬‬
Actual
Estimate
Earnings
Next:May 7, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪−0.16‬
‪−0.12‬
‪−0.08‬
‪−0.04‬
‪0.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

TSHA does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−60.00 M‬‬
‪0.00‬
‪‪60.00 M‬‬
‪‪120.00 M‬‬
‪‪180.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪50.00 M‬‬
‪‪100.00 M‬‬
‪‪150.00 M‬‬
‪‪200.00 M‬‬
Assets
Liabilities